Uromitexan

Uromitexan

mesna

Manufacturer:

Baxter Oncology

Distributor:

Transmedic
Concise Prescribing Info
Contents
Mesna
Indications/Uses
Prevention of urotoxic effects of oxazaphosphorines.
Dosage/Direction for Use
Tab Adult 40% of the dose of oxazaphosphorine (rounded to the nearest whole tab) to be taken at -2, 2 & 6 hr after oxazaphosphorine dosing. If Uromitexan is given by IV at 1st instance, the oral dose at -2 hr should be replaced by IV at 0 hr. Inj Adult Usually given at 20% of the dose of oxazaphosphorine at 0, 4 & 8 hr after administration of oxazaphosphorine. Childn Dose given at greater frequency (eg, 6 times) & at shorter intervals (eg, 3 hr). W/ very high-dose cytostatic therapy, total dose can be increased to 120% of the oxazaphosphorine dose.
Administration
May be taken with or without food.
Special Precautions
Protective effect applies only to the urinary tract. Oral mesna should be replaced by IV mesna in patients experiencing vomiting.
Adverse Reactions
GI effects, headache, malaise, limb & joint pains, depression, irritability, skin rash, hypotension, tachycardia, pseudoallergic reactions (rare).
ATC Classification
V03AF01 - mesna ; Belongs to the class of detoxifying agents used in antineoplastic treatment.
Presentation/Packing
Form
Uromitexan inj 400 mg
Packing/Price
(amp) 4 mL x 15 × 1's
Form
Uromitexan tab 400 mg
Packing/Price
10's
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $139 a year.
Sign up for free
Already a member? Sign in